Andrew W. Roberts
#154,749
Most Influential Person Now
Researcher
Andrew W. Roberts's AcademicInfluence.com Rankings
Andrew W. Robertscomputer-science Degrees
Computer Science
#8435
World Rank
#8868
Historical Rank
Computational Linguistics
#1880
World Rank
#1900
Historical Rank
Machine Learning
#3455
World Rank
#3498
Historical Rank
Artificial Intelligence
#3755
World Rank
#3810
Historical Rank
Download Badge
Computer Science
Andrew W. Roberts's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Andrew W. Roberts Influential?
(Suggest an Edit or Addition)Andrew W. Roberts's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets (2013) (2326)
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. (2016) (1405)
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. (2006) (1223)
- Programmed Anuclear Cell Death Delimits Platelet Life Span (2007) (925)
- SOCS3 negatively regulates IL-6 signaling in vivo (2003) (861)
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models (2016) (760)
- Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. (2012) (753)
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. (2016) (645)
- Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense. (1999) (613)
- The genomic landscape of hypodiploid acute lymphoblastic leukemia (2013) (585)
- Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. (1996) (549)
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. (2017) (520)
- RIPK1 Regulates RIPK3-MLKL-Driven Systemic Inflammation and Emergency Hematopoiesis (2014) (465)
- Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. (2007) (448)
- Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. (1998) (402)
- Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. (2009) (353)
- Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic (2006) (346)
- Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3 (2001) (325)
- G-CSF: A key regulator of neutrophil production, but that's not all! (2005) (317)
- Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. (1995) (295)
- SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. (2004) (292)
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. (2020) (290)
- Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. (2009) (290)
- Ibrutinib plus Venetoclax for the Treatment of Mantle‐Cell Lymphoma (2018) (282)
- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. (2017) (268)
- Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. (2011) (256)
- Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells (2010) (255)
- Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. (2018) (230)
- AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. (2018) (230)
- In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low‐dose interleukin‐2 for immunotherapy of advanced breast cancer patients (2010) (224)
- The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. (2016) (222)
- Rac and Cdc42 GTPases control hematopoietic stem cell shape, adhesion, migration, and mobilization (2001) (221)
- Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. (2019) (218)
- Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. (2017) (217)
- SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. (2006) (215)
- Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. (2018) (211)
- BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. (2018) (209)
- Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. (2004) (194)
- Targeting GM-CSF in inflammatory diseases (2016) (192)
- Granulocyte colony-stimulating factor and neutrophils—forgotten mediators of inflammatory disease (2006) (182)
- Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. (2012) (180)
- Role of the guanosine triphosphatase Rac2 in T helper 1 cell differentiation. (2000) (175)
- Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208 (2013) (172)
- Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets (2011) (170)
- A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis. (2008) (158)
- In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas (2008) (148)
- Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. (1997) (140)
- The Rac2 Guanosine Triphosphatase Regulates B Lymphocyte Antigen Receptor Responses and Chemotaxis and Is Required for Establishment of B-1a and Marginal Zone B Lymphocytes1 (2002) (135)
- Noncycling state of peripheral blood progenitor cells mobilized by granulocyte colony-stimulating factor and other cytokines. (1995) (135)
- Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. (2016) (134)
- Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. (2017) (134)
- Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. (2015) (131)
- Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. (2016) (129)
- Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma (2018) (124)
- The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs (2010) (122)
- Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. (2019) (120)
- Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC (2014) (118)
- Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. (2004) (113)
- Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1 (2018) (112)
- Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1β (2015) (112)
- Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (2018) (110)
- The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial (2015) (108)
- Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia (2018) (107)
- Targeting BCL-2-like Proteins to Kill Cancer Cells. (2016) (104)
- Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1 (2011) (102)
- The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia (2009) (100)
- Mouse loci for malaria-induced mortality and the control of parasitaemia (1997) (98)
- Structural Basis for Apoptosis Inhibition by Epstein-Barr Virus BHRF1 (2010) (98)
- Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. (2014) (97)
- A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia (2015) (95)
- GFI1B mutation causes a bleeding disorder with abnormal platelet function (2013) (94)
- The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis. (2005) (87)
- Targeting MCL-1 in hematologic malignancies: Rationale and progress. (2020) (85)
- Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) (2013) (83)
- A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (2015) (81)
- A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (2015) (81)
- A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. (2018) (80)
- MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML. (2018) (80)
- Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies (2015) (79)
- Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. (2014) (79)
- Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. (2020) (78)
- Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. (2007) (77)
- Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre‐transplant FDG‐PET scan following salvage chemotherapy (2010) (76)
- Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene (2006) (75)
- Regulation of interleukin‐1β by interferon‐γ is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin‐17 production (2010) (73)
- Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis (2011) (73)
- Multiple BCL2 mutations co-occurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. (2020) (72)
- The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma (2006) (72)
- Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival. (2012) (71)
- Cytokine production and function in c-mpl-deficient mice: no physiologic role for interleukin-3 in residual megakaryocyte and platelet production. (1998) (67)
- Broad inter‐individual variations in circulating progenitor cell numbers induced by granulocyte colony‐stimulating factor therapy (1995) (66)
- Rac2‐deficient mice display perturbed T‐cell distribution and chemotaxis, but only minor abnormalities in TH1 responses (2002) (65)
- The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. (2007) (65)
- Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow-up. (2020) (60)
- First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse (2014) (57)
- BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. (2020) (57)
- The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients (2013) (56)
- Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections (2004) (56)
- Absence of Suppressor of Cytokine Signalling 3 Reduces Self‐Renewal and Promotes Differentiation in Murine Embryonic Stem Cells (2006) (56)
- ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control. (2014) (54)
- IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3 (2011) (53)
- Genetic reduction of embryonic leukemia-inhibitory factor production rescues placentation in SOCS3-null embryos but does not prevent inflammatory disease. (2005) (52)
- Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) (2014) (51)
- Phase I First-inHuman Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (2017) (51)
- Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). (2009) (49)
- Statins enhance efficacy of venetoclax in blood cancers (2018) (49)
- The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study (2012) (49)
- A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma (2005) (49)
- Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia (2017) (48)
- Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study (2015) (48)
- Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study (2015) (48)
- Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis (2013) (47)
- Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease (2013) (47)
- Intact TP53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. (2021) (46)
- Neutrophils Require SHP1 To Regulate IL-1β Production and Prevent Inflammatory Skin Disease (2011) (45)
- Granulocyte colony-stimulating factor induces selective elevations of progenitor cells in the peripheral blood of mice. (1994) (44)
- Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis (2018) (43)
- Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing (2020) (42)
- Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies (2011) (42)
- SOCS3 regulates graft-versus-host disease. (2010) (41)
- Dok-related protein negatively regulates T cell development via its RasGTPase-activating protein and Nck docking sites (2002) (39)
- Therapeutic development and current uses of BCL-2 inhibition. (2020) (37)
- An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis, (2011) (37)
- Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (2016) (37)
- Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. (2006) (37)
- Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma (2020) (35)
- Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). (2013) (35)
- An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (2008) (32)
- A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation (2007) (31)
- Fas regulates neutrophil lifespan during viral and bacterial infection (2015) (31)
- Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. (2011) (31)
- Socs3 maintains the specificity of biological responses to cytokine signals during granulocyte and macrophage differentiation. (2008) (31)
- Hematopoietic abnormalities in mice deficient in gp130-mediated STAT signaling. (2002) (30)
- First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) Trial of Thalidomide and Alternate Day Prednisolone Following Autologous Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (ALLG MM6). (2006) (29)
- Studies of the c‐Mpl Thrombopoietin Receptor through Gene Disruption and Activation (1996) (29)
- Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in mice (2010) (29)
- Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma (2009) (29)
- A phase I study of anti-CD123 monoclonal antibody (mAb) CSL360 targeting leukemia stem cells (LSC) in AML. (2010) (28)
- Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma (2019) (28)
- Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies (2021) (27)
- BCL2 inhibitors and MCL1 inhibitors for hematological malignancies. (2021) (27)
- A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. (2007) (25)
- Studying Leaders and Elites: The Personal Biography Approach (2020) (25)
- Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition (2021) (24)
- BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis (2013) (24)
- Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. (2020) (24)
- Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation (2019) (24)
- Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells (2020) (24)
- ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). (2016) (23)
- A Phase 1 and Correlative Biological Study of CSL360 (anti-CD123 mAb) in AML (2008) (23)
- Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma (2016) (23)
- Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study (2019) (23)
- Current challenges and novel treatment strategies in double hit lymphomas (2016) (22)
- Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial (2019) (22)
- Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis (2012) (22)
- A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation (2004) (22)
- Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. (2003) (21)
- Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results (2015) (20)
- Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study (2021) (20)
- Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263). (2013) (20)
- Regulation of multiple cytokine signalling pathways by SOCS3 is independent of SOCS2 (2009) (20)
- Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study (2015) (20)
- BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB‐3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) (2017) (20)
- Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia. (2016) (19)
- BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib (2019) (19)
- Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. (2020) (19)
- ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study. (2014) (19)
- Bisphosphonate guidelines for treatment and prevention of myeloma bone disease (2017) (19)
- The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study. (2016) (19)
- Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. (2021) (19)
- PS1159 POOLED ANALYSIS OF SAFETY DATA FROM MONOTHERAPY STUDIES OF THE BRUTON TYROSINE KINASE (BTK) INHIBITOR, ZANUBRUTINIB (BGB-3111), IN B-CELL MALIGNANCIES (2019) (18)
- Rapid Inflammation in Mice Lacking Both SOCS1 and SOCS3 in Hematopoietic Cells (2016) (18)
- Problem Based Learning and the Design Studio (2004) (18)
- Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood (2006) (17)
- Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. (2018) (17)
- Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders (2006) (17)
- Mechanism of crosstalk inhibition of IL-6 signaling in response to LPS and TNFα (2007) (16)
- Graft-versus-lymphoma effect in progressive hepatosplenic gamma/delta T-cell lymphoma (2007) (16)
- Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants (2008) (15)
- Do steady-state peripheral blood progenitor cell (PBPC) counts predict the yield of PBPC mobilized by filgrastim alone? (1995) (15)
- Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. (2017) (15)
- Efficacy of venetoclax plus rituximab for relapsed CLL: Five-year follow-up of continuous or limited-duration therapy. (2021) (15)
- High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study (2016) (15)
- Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study) (2018) (15)
- Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma (2019) (14)
- Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). (2013) (14)
- Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (2016) (14)
- A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma (2019) (14)
- Venetoclax in Lymphoid Malignancies: New Insights, More to Learn. (2019) (14)
- Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL). (2016) (13)
- Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16) (2020) (13)
- Reduction in platelet counts as a mechanistic biomarker and guide for adaptive dose-escalation in phase I studies of the Bcl-2 family inhibitor ABT-263 (2008) (13)
- Results of a phase 2 study of pacritinib ( SB 1518 ) , a JAK 2 / JAK 2 ( V 617 F ) inhibitor , in patients with myelo fi brosis (2015) (13)
- Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction (2013) (13)
- Venetoclax: a primer. (2017) (13)
- CSL362: A Monoclonal Antibody to Human Interleukin-3 Receptor (CD123), Optimized for NK Cell-Mediated Cytotoxicity of AML Stem Cells (2012) (12)
- Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach (2022) (12)
- Mobilization of dendritic cells in cancer patients treated with granulocyte colony‐stimulating factor and chemotherapy (2002) (12)
- The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study (2012) (12)
- Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group (2015) (12)
- G-CSF-mobilized peripheral blood progenitor cells: in vitro growth pattern and hematopoietic growth factor receptor profile. (1997) (12)
- Validating the Allogeneic Stem Cell Transplantation Disease Risk Index: Sample Size, Follow-up, and Local Data Are Important (2015) (12)
- More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders. (2006) (12)
- Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL (2019) (12)
- Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing (2021) (11)
- An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). (2008) (11)
- Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study (2008) (11)
- Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (2015) (10)
- Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies (2010) (10)
- Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (2015) (10)
- Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (2015) (10)
- Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia (2020) (10)
- Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group (2017) (9)
- Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study. (2014) (9)
- Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study. (2017) (9)
- Single-cell multiomics reveal the scale of multi-layered adaptations enabling CLL relapse during venetoclax therapy. (2022) (9)
- The Rac 2 Guanosine Triphosphatase Regulates B Lymphocyte Antigen Receptor Responses and Chemotaxis and Is Required for Establishment of B-1 a and Marginal Zone B Lymphocytes 1 (2002) (9)
- Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. (2020) (9)
- Perturbed thymopoiesis in vitro in the absence of suppressor of cytokine signalling 1 and 3. (2008) (9)
- Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group (2015) (8)
- Ongoing phase I studies of ABT-263: Mitigating Bcl-XL induced thrombocytopenia with lead-in and continuous dosing. (2009) (8)
- Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: Outcome and Minimal Residual Disease (MRD) from the Full Population of the Pivotal M13-982 Trial (2017) (8)
- Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia (2016) (8)
- Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab (2018) (7)
- Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study (2019) (7)
- Minimal Residual Disease (MRD) As Exploratory Endpoint in a Phase 1 Study of the Anti-CD123 Mab CSL362 Given As Post-Remission Therapy in Adult Acute Myeloid Leukemia (AML) (2015) (7)
- Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study. (2017) (7)
- Bortezomib: Putting mantle cell lymphoma on death row (2008) (6)
- COMBINATION IBRUTINIB (IBR) AND VENETOCLAX (VEN) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): PRIMARY ENDPOINT ASSESSMENT OF THE PHASE 2 AIM STUDY (2017) (6)
- Phase II study of glycosylated recombinant human granulocyte colony-stimulating factor after HLA-identical sibling bone marrow transplantation. (1994) (6)
- Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib. (2020) (6)
- Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors (2021) (6)
- Napoleon: A Life (2014) (6)
- Genome-Wide Analysis of Genetic Alterations in Chronic Myelogenous Leukemia. (2008) (6)
- Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia (2018) (6)
- New Agents to Treat Chronic Lymphocytic Leukemia. (2016) (5)
- Germline loss of MBD4 predisposes to leukaemia due to a mutagenic cascade driven by 5mC (2017) (5)
- Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM). (2015) (5)
- Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study (2013) (5)
- The regulation of hematopoiesis in max 41 transgenic mice with sustained excess granulopoiesis. (1996) (5)
- Impact of Number of Prior Therapies and Bulk of Disease on Outcomes with Venetoclax (VEN) Monotherapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) (2017) (5)
- Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study (2019) (5)
- High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia (2020) (5)
- Towards a four-dimensional view of neutrophils. (2012) (5)
- 5.23 Phase 2 Study of Navitoclax (ABT-263) Safety and Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Interim Results (2011) (5)
- Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance (2022) (5)
- Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (2016) (5)
- Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia (2018) (5)
- Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers (2019) (4)
- Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip. (2004) (4)
- Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia? (2019) (4)
- Germline loss-of-function variants in the base-excision repair gene MBD4 cause a Mendelian recessive syndrome of adenomatous colorectal polyposis and acute myeloid leukaemia (2021) (4)
- Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax (2016) (4)
- Abstract PD1-06: A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2–positive metastatic breast cancer (MBC) (2019) (4)
- in blood cancers. (2019) (4)
- No evidence for an adverse interaction between zoledronic acid and thalidomide Preliminary safety analysis from the Australasian leukaemia and lymphoma group MM6 Myeloma Trial (2003) (4)
- Aberrant G-CSF- and IL-6-Induced Proliferation and Differentiation in Suppressor of Cytokine Signaling-3 (SOCS3)-Deficient Progenitor Cells. (2004) (4)
- Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. (2016) (4)
- Dilemmas of collaboration (4)
- Acquired mutations in BAX confer resistance to BH3-mimetic therapy in Acute Myeloid Leukemia. (2022) (4)
- BH3-mimetics – the solution to chemoresistance? (2009) (4)
- Forensic Face Matching (2021) (4)
- Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma (2015) (4)
- Hearing the Student Voice (2010) (4)
- BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia (2020) (4)
- A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2-positive metastatic breast cancer (2018) (3)
- What If? 2 (2001) (3)
- Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax (2019) (3)
- Cross-Study Multivariable Analysis of the Impact of Adding Rituximab to Venetoclax on the Depth and Durability of Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (2016) (3)
- SOCS 3 regulates graft-versus-host disease (2010) (3)
- VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON‐HODGKIN LYMPHOMA (NHL) (2017) (3)
- The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16) (2020) (3)
- Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy (2021) (3)
- Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated-G-CSF. (2005) (2)
- BH3 mimetic therapy: an emerging and promising approach to treating chronic lymphocytic leukemia (2013) (2)
- Long-Term Follow-up of Patients with Mantle Cell Lymphoma Treated with Venetoclax Monotherapy (2018) (2)
- High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial (2022) (2)
- Scotland the brave. (2009) (2)
- Biomarkers and In Vivo Responses to the BH3 Mimetic, ABT-263, in Patients (pts) with Chronic Lymphocytic Leukemia (CLL). (2009) (2)
- Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD) (2021) (2)
- Researching the Student (2009) (2)
- The Aachen Memorandum (1995) (2)
- GFI1B Mutation Causes a Platelet Function Defect With Reduced Alpha-Granule Content and Abnormal Aggregation Response (2013) (2)
- Title : Clinico-pathological features and outcomes of progression of CLL on the BCL 2 inhibitor venetoclax Running Title : CLL progression on venetoclax (2017) (2)
- A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (2017) (2)
- The Bcl-2 Protein Family Is Essential for Platelet Survival In Vivo. (2006) (2)
- Rare haematologic malignancies: Bad diseases can have great outcomes when the right treatments are discovered (2015) (2)
- Adding Student Video Projects to Physics Courses (2019) (2)
- Renal safety evaluation of zoledronic acid and thalidomide when used as post-stem cell transplant maintenance therapy in multiple myeloma. (2004) (1)
- ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial (2022) (1)
- Targeting apoptotic pathways to treat lymphoid malignancies. (2016) (1)
- The People’s War (2012) (1)
- Long Term Outcomes of Venetoclax Therapy for Complex Karyotype Relapsed/Refractory Chronic Lymphocytic Leukemia (2018) (1)
- Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL. (2018) (1)
- S146: VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION: 6-YEAR FOLLOW-UP AND GENOMIC ANALYSES IN A PIVOTAL PHASE 2 TRIAL (2022) (1)
- BCL2 inhibition in double hit lymphoma (2015) (1)
- Citizen rule (2020) (1)
- Megakaryocytes Possess a Functional Intrinsic Apoptosis Pathway That Must Be Restrained In Order to Survive and Produce Platelets (2010) (1)
- The New Grove (1981) (1)
- Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations (2019) (1)
- Venetoclax (VEN) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). (2017) (1)
- Venetoclax for the treatment of mantle cell lymphoma (2019) (1)
- Can Financial Markets Be Trusted (1997) (1)
- RAPID COMMUNICATION Deficiencies in Progenitor Cells of Multiple Hematopoietic Lineages and Defective Megakaryocytopoiesis in Mice Lacking the Thrombopoietin Receptor c-Mpl (2002) (1)
- IDENTIFICATION OF POTENT BH3-MIMETIC COMBINATIONS TARGETING PRO-SURVIVAL PATHWAYS IN HUMAN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (2018) (1)
- The BH3 Mimetic, ABT-737, Is Effective Against Bcl-2 Overexpressing Lymphoid Tumors. (2006) (1)
- TARGETED THERAPIES IN HAEMATOLOGICAL MALIGNANCIES (2008) (1)
- Phase 1/2 Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Venetoclax in Japanese Subjects with Chronic Lymphocytic Leukemia (2017) (1)
- OUTCOMES WITH BRUTON TYROSINE KINASE INHIBITION IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA AFTER PROGRESSION ON VENETOCLAX (2017) (1)
- Quality of life (QOL) assessment in patients with relapsed/refractory multiple myeloma (MM) treated with thalidomide (T) plus celecoxib (Cxb) (2005) (1)
- White judges under attack (1969) (1)
- Acquired Clinical Resistance to IDH2 Inhibitors: Leukemia Finds Multiple Avenues for Escape (2018) (1)
- Suppressor of Cytokine Signaling-3 (SOCS3) Selectively Modulates Progenitor Cell Proliferation and Differentiation Induced by G-CSF and IL-6, and the Synergy between SCF and IL-6. (2006) (1)
- A phase 2 open-label study of the efficacy of ABT-199 (GDC-0199) in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) harboring 17p deletion. (2014) (1)
- The BH3 Mimetic, ABT-737, Is Effective Against Bcl-2 Overexpressing Lymphoid Tumors. (2006) (1)
- RESISTANCE TO VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) (2019) (1)
- Phase 1b Interim Results: Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) in Relapsed/Refractory (R/R) Multiple Myeloma (MM) (2015) (1)
- Feuersturm (2019) (0)
- Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199 (2014) (0)
- Fas Controls Neutrophil Lifespan during Bacterial and Viral Infection (2014) (0)
- Necroptotic Death Of RIPK1-Deficient HSC Compromises Hematopoiesis (2013) (0)
- Expansion of Autologous Human V gamma 9V delta 2 T Cells Ex Vivo: Potential for Adoptive T Cell Therapy of Prostate Cancer (2010) (0)
- AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/ REFRACTORY CLL (2019) (0)
- Zoledronic Acid Plus Thalidomide Is Safe and Well Tolerated When Used as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Nonprogressive Multiple Myeloma. (2005) (0)
- Immunohistochemical (IHC) biomarkers associated with response and survival following lenalidomide and prednisolone maintenance post-ASCT in patients with MM: an exploratory, hypothesis generating sub-study of the LEOPARD trial (2015) (0)
- IDENTIFYING GENETIC MODIFIERS OF BREAST CANCER RISK IN BRCA1 AND BRCA2 MUTATION CARRIERS IN THE CONSORTIUM OF INVESTIGATORS OF MODIFIERS OF BRCA1 AND BRCA2 (CIMBA) (2007) (0)
- Cytokines and placentation: The role of SOCS proteins (2006) (0)
- Targeted Therapy to Trigger GVL: A Case for the Prosecution in FLT3-ITD–Mutant AML (2018) (0)
- Stopping Imatinib in CML: Safe in the Long Term for Deep Molecular Responders As the Immune System Steps Up (2017) (0)
- Tissue Iron Overload Is Common Post Transplantation (Allo BMT) and Is Associated with Red Cell Transfusion Load and HFE Genotype. (2004) (0)
- Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation. (2007) (0)
- Abstract SY16-01: Optimizing BH3 mimetic therapy: Insights from BCL2 inhibition in the clinic (2016) (0)
- All-trans retinoic acid--chemotherapy interactions in acute promyelocytic leukaemia. (1992) (0)
- Outcomes following the addition of rituximab to R/R CLL patients progressing after durable responses on venetoclax monotherapy (2020) (0)
- BCL2 Inhibitors: Insights into Resistance (2018) (0)
- 69 ABT-199, a Selective Small Molecule Inhibitor of Bcl-2, Exhibits Efficacy in Bcl-2 Dependent Malignancies While Sparing Platelets (2012) (0)
- Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma (2018) (0)
- Undetectable minimal residual disease should be the goal of venetoclax therapy in relapsed and refractory chronic lymphocytic leukaemia (2020) (0)
- Lighting the Path to Personalized Medicine for Hematologic Malignancies: Lessons From an AML Knowledge Bank (2018) (0)
- An immunocompetent E mu-myc mouse B leukemia/lymphoma model for studying Bcl-2 related chemoresistance in vivo. (2003) (0)
- 49 Regulation of Apoptosis by the Bcl-2 Family (2012) (0)
- Acute leukaemia in Australia: outcomes have improved, but there is still much to do (2022) (0)
- Deep Profiling of Chronic Lymphocytic Leukaemia (CLL) and Healthy Immune Cells By Mass Cytometry Resolves Impacts of Venetoclax Pressure (2021) (0)
- Targeting Mcl-1 is a promising strategy to kill mantle cell lymphoma cells (2019) (0)
- The complement regulator CD46 regulates unconventional gammadelta T cell responses (2010) (0)
- SOCS3 Regulates Th1 Dependent Acute Graft-Versus Host Disease (2008) (0)
- The Role of BAX/BAK-Mediated Apoptosis for the Cytotoxic Action of Anti-Myeloma Agents (2016) (0)
- Granulocyte Colony-Stimulating Factor (G-CSF) (2003) (0)
- A Genetic Mutation on Murine Chromosome 7 Causes Thrombocytosis Associated with Thrombopoietin Excess - A Model of Jak2V617F Negative Idiopathic Thrombocytosis. (2005) (0)
- Complete Remission on 18F-FDG-PET Prior to Autologous Stem Cell Transplantation Predicts Superior Event Free Survival of Patients with Relapsed or Refractory Hodgkin Lymphoma. (2008) (0)
- Administered G-CSF boosts low affinity antibody production during T cell-dependent responses (2009) (0)
- Donald Metcalf (1929–2014) (2015) (0)
- Discovery of BCL-2 as an Oncogene and the First Inhibitor of Apoptosis (2016) (0)
- Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival (2016) (0)
- CHIP and Coronary Heart Disease: Clonal Hematopoiesis Increases Atherosclerosis (2017) (0)
- 126: Inflammasome activation due to polymerized actin triggers an autoinflammatory disease that is dependent on IL-18, not IL-1β (2014) (0)
- Genetic Approaches to the Investigation of the Mechanisms of Hematopoietic Progenitor Cell Mobilization into the Blood (1999) (0)
- Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation (2019) (0)
- Optimal regimens for the mobilization and collection of peripheral blood progenitor cells from normal donors. (1997) (0)
- A215 Post-ASCT Thalidomide Consolidation Further Prolongs PFS For Patients who Have Already Achieved A Complete Remission (2009) (0)
- Reduced-intensity allogeneic hemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders (2006) (0)
- Single-Centre Validation Of a Disease Risk Index For Estimating Survival and Relapse In Allogeneic Hematopoietic Stem Cell Transplant Recipients: Sample Size, Adequate Follow-Up, and Use Of Local Data Are Vital Considerations (2013) (0)
- Bim Is the Critical, and Bad and Bmf Are the Ancillary BH3-Only Proteins for Imatinib Mesylate-Induced Apoptosis of Bcr/Abl-Positive Leukemias. (2005) (0)
- coordinately regulate megakaryocyte survival L (2013) (0)
- Role for Interleukin-3 in Residual Megakaryocyte and Platelet Production Deficient Mice: No Physiologic - mpl Cytokine Production and Function in c- (2011) (0)
- Can Chemoimmunotherapy Be Improved As Front-Line Therapy for CLL in Fit Patients? (2017) (0)
- Deciphering the Dilemmas Posed by Detection of Mutant Myeloid Clones (2018) (0)
- Venetoclax Plus Rituximab can Achieve Durable Treatment-Free Remission in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (2016) (0)
- lymphoproliferative diseases before receiving Navitoclax (ABT-263) Low adhesion receptor levels on circulating platelets in patients with (2013) (0)
- Use of an anti-g-csf or anti-g -csfr antibody or a soluble g- csfr for the treatment or prophylaxis of arthritis (2003) (0)
- ARE THE BCL2 FAMILY INHIBITORS SUBSTRATES FOR THE MULTIDRUG RESISTANCE EFFLUX PUMP MDR1? (2019) (0)
- A novel means of immunoregulation: CD46 attenuates effector responses of human conventional and unconventional T cells by distinct mechanisms (138.8) (2010) (0)
- A Randomized Trial in a Rare Cancer: Targeting CD30 in Cutaneous T Cell Lymphoma Yields Therapeutic Dividends (2017) (0)
- Differential Targeting of Pro-Survival Bcl-2 Proteins by Their Pro-Apoptotic BH3-Only Ligands: Implications for Targeted Therapies. (2004) (0)
- New Agents to Treat Chronic Lymphocytic Leukemia REPLY (2016) (0)
- Corrigendum (2004) (0)
- LEOPARD: A Phase II Study of Post Autologous Stem Cell Transplantation (ASCT) Maintenance Lenalidomide and Prednisolone for Myeloma (MM), Incorporating Minimal Residual Disease (MRD) Assessments (2013) (0)
- Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments (2014) (0)
- Antimicrobials post transplant A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation (2004) (0)
- Structural basis for the inhibition of apoptosis by Epstein–Barr virus BHRF1 (2011) (0)
- Functional redundancy of SOCS3 (2009) (0)
- A method for treatment and prophylaxis. (2003) (0)
- 1017 - TRANSLATIONAL LESSONS IN OPTIMIZING CLINICAL USE OF BH3 MIMETICS TO TREAT HEMATOLOGICAL MALIGNANCIES (2019) (0)
- Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD) (2022) (0)
- Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells (2020) (0)
- Venetoclax treatment in cancer patients has limited impact on circulating T and NK cells. (2022) (0)
- Not All Large Cells Are Created Equal: Is Genomic Classification the New Frontier in Diffuse Large B-cell Lymphoma? (2018) (0)
- Abstract 1366:MBD4guards against DNA damage from methylcytosine deamination (2018) (0)
- AMulticenter Phase II TrialofThalidomide andCelecoxib for Patients with Relapsed and RefractoryMultipleMyeloma (2005) (0)
- 55 patients with myeloproliferative disorders in EP300 and MYB More on Myb in myelofibrosis: molecular analyses of (2011) (0)
- Low Predictive Value of Functional Imaging with 18FDG-PET or Gallium Scanning in Relapsed or Refractory Hodgkin Lymphoma Prior to Autologous Stem Cell Transplantation. (2007) (0)
- PL1-5 IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3 (2010) (0)
- Targeting the Pro-Survival BCL2 Proteins with BH3 Mimetic Compounds for Treating Multiple Myeloma (2016) (0)
- Do Statins Enhance the Anti-Cancer Activity of Venetoclax? (2017) (0)
- Relapsed CLL: A Problem, Not Yet Solved (2017) (0)
- Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia Under Long-Term Venetoclax Treatment (2018) (0)
- Complexity of DNA Repair From Alcohol Damage Revealed (2018) (0)
- G‐CSF induces leukocyte recruitment in vivo via the leukocyte G‐CSF receptor (2008) (0)
- Reply to M. Cavo (2009) (0)
- ENU Mutagenesis Screen Identifies a Novel Regulator of Platelet Production. (2004) (0)
- RESPONSE OF CML TO MEK INHIBITION 1-1-Cellular mechanisms underlying complete hematological response of chronic myeloid leukemia to BRAF and MEK 1 / 2 inhibition in a patient with concomitant metastatic melanoma (2015) (0)
- A Pilot Study To Explore the Tolerability and Efficacy of Thalidomide Containing Regimens To Reduce Tumour Cell Load Prior to HSC in Multiple Myeloma and the Feasibility of Harvesting HSC Following Thalidomide Containing Regimens. (2005) (0)
- 34 ORAL Advantages of a modified continual reassessment method (CRM) for dose finding studies: experience in ongoing phase I trials with ABT-263 (2008) (0)
- 5th European Workshop on Immune-Mediated Inflammatory Diseases (2010) (0)
- Megakaryocytes possess functional apoptotic pathways that must be restrained in order to survive and produce platelets (2011) (0)
- Introduction to a review series on small molecule targeted therapies for lymphoid malignancies. (2021) (0)
- Targeting Lymphoid Malignancies with Small Molecule Inhibitors of Pro-Survival Bcl-2 Proteins. (2005) (0)
- Arthur Bryant and Hitler (2006) (0)
- Citizenship (2020) (0)
- The house of Windsor (2000) (0)
- Manipulation in Perspective (1990) (0)
- Changing of the guard…the old and the new. (2020) (0)
- Prospects for Haydn Biography (1982) (0)
- Stanley Baker (2020) (0)
- There is a Gate (2014) (0)
- What's wrong with teachers today (2001) (0)
- Flashman goes to Westminster (1995) (0)
- James Robertson Justice (2020) (0)
- Margaret Rutherford (2020) (0)
- Debate: Was Napoleon Great? (2015) (0)
- Conclusion (2020) (0)
- Terry-Thomas and Leslie Phillips (2020) (0)
- Sylvia Syms (2020) (0)
- Sidney James (2020) (0)
- Richard Gray, 1929–2005 (2005) (0)
- A protocol for the assessment of dementia (2006) (0)
- The year we stood alone (1994) (0)
- Letters From the Front (2008) (0)
- Peter Finch (2020) (0)
- Napoleón y Wellington (2003) (0)
- Hot but Unheroic (1992) (0)
- The Storm of War (2009) (0)
- MDA/GCG Mineralogical Terminology Meeting (1981) (0)
- The Ash Grove (1983) (0)
- The EU’s Real Haider Problem (2000) (0)
- Introduction (2020) (0)
- What Might Have Been (2005) (0)
- Jack Hawkins (2020) (0)
- Hattie Jacques (2020) (0)
- Made to measure (2004) (0)
- Norman Wisdom (2020) (0)
- Angels of War (2010) (0)
- The one and only Diana Dors (2020) (0)
- AFH volume 31 issue 3 Cover and Back matter (1990) (0)
- Peter Sellers (2020) (0)
- Napoleon and the British (2006) (0)
- Know Your Bulbs (2017) (0)
- Regulators in algebraic geometry (2002) (0)
- John Mills (2020) (0)
- Privacy, Punishment and Private Law (2021) (0)
- Václav Havel by Williams, Kieran (2017) (0)
- Kenneth More (2020) (0)
- Laurence Harvey (2020) (0)
- Proton pairing correlation studies (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Andrew W. Roberts?
Andrew W. Roberts is affiliated with the following schools:
